| Product Code: ETC8930059 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The Republic of North Macedonia continues to rely on imported insulin biosimilars, with top exporting countries in 2024 being the UK, USA, China, Sweden, and Japan. Despite high concentration levels indicated by the HHI, the market shows strong growth potential with a CAGR of 9.15% from 2020 to 2024. The growth rate for 2023-24 at 10.69% further highlights the increasing demand for insulin biosimilars in North Macedonia, presenting opportunities for further market expansion and development in the coming years.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Republic of Macedonia Insulin Biosimilars Market Overview |
3.1 Republic of Macedonia Country Macro Economic Indicators |
3.2 Republic of Macedonia Insulin Biosimilars Market Revenues & Volume, 2021 & 2031F |
3.3 Republic of Macedonia Insulin Biosimilars Market - Industry Life Cycle |
3.4 Republic of Macedonia Insulin Biosimilars Market - Porter's Five Forces |
3.5 Republic of Macedonia Insulin Biosimilars Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.6 Republic of Macedonia Insulin Biosimilars Market Revenues & Volume Share, By Indicative, 2021 & 2031F |
3.7 Republic of Macedonia Insulin Biosimilars Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Republic of Macedonia Insulin Biosimilars Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Republic of Macedonia Insulin Biosimilars Market Trends |
6 Republic of Macedonia Insulin Biosimilars Market, By Types |
6.1 Republic of Macedonia Insulin Biosimilars Market, By Product Type |
6.1.1 Overview and Analysis |
6.1.2 Republic of Macedonia Insulin Biosimilars Market Revenues & Volume, By Product Type, 2021- 2031F |
6.1.3 Republic of Macedonia Insulin Biosimilars Market Revenues & Volume, By Rapid-acting biosimilar, 2021- 2031F |
6.1.4 Republic of Macedonia Insulin Biosimilars Market Revenues & Volume, By Long-acting biosimilar, 2021- 2031F |
6.1.5 Republic of Macedonia Insulin Biosimilars Market Revenues & Volume, By Premixed biosimilar, 2021- 2031F |
6.2 Republic of Macedonia Insulin Biosimilars Market, By Indicative |
6.2.1 Overview and Analysis |
6.2.2 Republic of Macedonia Insulin Biosimilars Market Revenues & Volume, By Type I Diabetes, 2021- 2031F |
6.2.3 Republic of Macedonia Insulin Biosimilars Market Revenues & Volume, By Type II Diabetes, 2021- 2031F |
6.3 Republic of Macedonia Insulin Biosimilars Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 Republic of Macedonia Insulin Biosimilars Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Republic of Macedonia Insulin Biosimilars Market Revenues & Volume, By Ambulatory Surgical Centers, 2021- 2031F |
6.3.4 Republic of Macedonia Insulin Biosimilars Market Revenues & Volume, By Others, 2021- 2031F |
7 Republic of Macedonia Insulin Biosimilars Market Import-Export Trade Statistics |
7.1 Republic of Macedonia Insulin Biosimilars Market Export to Major Countries |
7.2 Republic of Macedonia Insulin Biosimilars Market Imports from Major Countries |
8 Republic of Macedonia Insulin Biosimilars Market Key Performance Indicators |
9 Republic of Macedonia Insulin Biosimilars Market - Opportunity Assessment |
9.1 Republic of Macedonia Insulin Biosimilars Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.2 Republic of Macedonia Insulin Biosimilars Market Opportunity Assessment, By Indicative, 2021 & 2031F |
9.3 Republic of Macedonia Insulin Biosimilars Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Republic of Macedonia Insulin Biosimilars Market - Competitive Landscape |
10.1 Republic of Macedonia Insulin Biosimilars Market Revenue Share, By Companies, 2024 |
10.2 Republic of Macedonia Insulin Biosimilars Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |